Literature DB >> 2676561

Expression and function of HLA-A2.1 in transgenic mice.

H Epstein1, R Hardy, J S May, M H Johnson, N Holmes.   

Abstract

We have derived a number of transgenic mouse lines which express the human major histocompatibility complex class I gene HLA-A2.1. Two lines carry the complete human HLA-A2.1, the others bear a recombinant gene in which the HLA-A2.1 coding regions are fused to the H-2Kb promoter. Analysis of transgenic spleen cells by immunofluorescence demonstrates that these mouse cells express HLA-A2.1 on their surface in association with mouse beta 2-microglobulin (beta 2m), confirming that HLA-A2 does not require human beta 2m to be expressed at the cell surface. The cells contain more HLA mRNA than endogenous H-2 class I mRNA. There is also a large pool of non-beta 2m-associated HLA heavy chain inside the cell. In contrast the amount of HLA:beta 2m complex is low. Thus, in transgenic mice HLA-A2 seems to compete poorly with H-2 heavy chains for mouse beta 2m. The HLA-A2.1 transgenic mice do not produce influenza-virus-specific cytotoxic T cells (CTL) restricted to the HLA transgene, at least in sufficient numbers to be measured in a direct bulk CTL assay. The dominance of H-2-restricted clones may be the result of quantitative rather than qualitative factors. However, HLA-A2.1 transgenic spleen cells are effective in stimulating an allogeneic CTL response in normal mice. This response is not H-2 restricted. Cold target inhibition studies show that there are at least two populations of CTL, one of which is specific for HLA-A2.1 on mouse cells. This result suggests that at least some allo-CTL are directed against major histocompatibility complex plus "self-peptide".

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676561     DOI: 10.1002/eji.1830190909

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease.

Authors:  Paul E Makidon; Douglas M Smith; Jeffery V Groom Ii; Zhengyi Cao; Jeffery J Landers; James R Baker
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

2.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

3.  Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.

Authors:  P Escobar; Z Yu; A Terskikh; N Holmes; G Corradin; J P Mach; F Healy
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.

Authors:  Rachid Boucherma; Hédia Kridane-Miledi; Romain Bouziat; Michael Rasmussen; Tanja Gatard; Francina Langa-Vives; Brigitte Lemercier; Annick Lim; Marion Bérard; Lbachir Benmohamed; Søren Buus; Ronald Rooke; François A Lemonnier
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

5.  Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes.

Authors:  A P Warren; D H Ducroq; P J Lehner; L K Borysiewicz
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex.

Authors:  A Vitiello; D Marchesini; J Furze; L A Sherman; R W Chesnut
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

7.  HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.

Authors:  S Pascolo; N Bervas; J M Ure; A G Smith; F A Lemonnier; B Pérarnau
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

8.  Development of a humanized HLA-A30 transgenic mouse model.

Authors:  Meng-Min Zhu; Bo-Wen Niu; Ling-Ling Liu; Hua Yang; Bo-Yin Qin; Xiu-Hua Peng; Li-Xiang Chen; Yang Liu; Chao Wang; Xiao-Nan Ren; Chun-Hua Xu; Xiao-Hui Zhou; Feng Li
Journal:  Animal Model Exp Med       Date:  2022-07-06

9.  The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4.

Authors:  D M Altmann; D C Douek; A J Frater; C M Hetherington; H Inoko; J I Elliott
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  Relationship between Poor Immunogenicity of HLA-A2-Restricted Peptide Epitopes and Paucity of Naïve CD8(+) T-Cell Precursors in HLA-A2-Transgenic Mice.

Authors:  Yoon Seok Choi; Dong Ho Lee; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2014-08-22       Impact factor: 6.303

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.